BIOFILCHEM vs NATCOPHARM: Stock Comparison

Biofil Chemicals & Pharmaceuticals Limited vs Natco Pharma Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Natco Pharma Limited is the larger company by market capitalisation. Biofil Chemicals & Pharmaceuticals Limited shows faster revenue growth, while Natco Pharma Limited shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Biofil Chemicals & Pharmaceuticals Limited and Natco Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BIOFILCHEM is more favourable on 4 of 11 scored metrics and NATCOPHARM on 7These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NATCOPHARM is the larger company
₹16,536 Cr vs ₹53 Cr
EPS
NATCOPHARM has higher earnings per share
₹79.24 vs ₹1.71
Dividend Yield
NATCOPHARM has a higher dividend yield
0.52% vs 0%
Revenue Growth (TTM YoY)
BIOFILCHEM has faster revenue growth
-9.3% vs -39.6%
EPS Growth (TTM YoY)
BIOFILCHEM has faster EPS growth
10.8% vs -34.1%
Qtr Sales Growth
BIOFILCHEM has stronger quarterly sales growth
-9.34% vs -39.5%
Qtr Profit Growth
BIOFILCHEM has stronger quarterly profit growth
5% vs -34.1%
ROE
NATCOPHARM has a higher ROE
16.9% vs 13.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOFILCHEMNATCOPHARM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOFILCHEMNATCOPHARM
Live Price₹32.64₹925.05
Day Change-0.55%-0.22%
Volume4,0481.52 L
52-Week High₹46.34₹1,226.8
52-Week Low₹25.6₹789
Distance from 52W High-29.56%-24.6%

Valuation

MetricBIOFILCHEMNATCOPHARM
Market Cap₹53 Cr₹16,536 Cr
P/E Ratio11.68x
P/B Ratio1.8x
EPS₹1.71₹79.24
Book Value₹13.21₹514.92
Dividend Yield0%0.52%

Growth

MetricBIOFILCHEMNATCOPHARM
Revenue Growth (TTM YoY)-9.3%-39.6%
EPS Growth (TTM YoY)10.8%-34.1%
Qtr Sales Growth-9.34%-39.5%
Qtr Profit Growth5%-34.1%

Profitability & Leverage

MetricBIOFILCHEMNATCOPHARM
ROE13.8%16.9%
ROCE15.8%17.1%
Net Margin9.81%34.78%
Operating Margin2.29%35.2%
Debt to Equity0.14x0.08x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOFILCHEMNATCOPHARM
Promoter Holding46.79%49.14%
FII Holding0%16.99% 0.38 pp
DII Holding0.08%5.62% 0.16 pp
Public Holding53.13%27.97% 0.22 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Biofil Chemicals & Pharmaceuticals Limited and Natco Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.